title: Indications, usage, and dosage of the transfer factor.
abstract: The transfer factor (TF) was described in 1955 by S. Lawrence. In 1992 Kirkpatrick characterized the specific TF at molecular level. The TF is constituted by a group of numerous molecules, of low molecular weight, from 1.0 to 6.0 kDa. The 5 kDa fraction corresponds to the TF specific to antigens. There are a number of publications about the clinical indications of the TF for diverse diseases, in particular those where the cellular immune response is compromised or in those where there is a deficient regulation of the immune response. In this article we present our clinical and basic experiences, especially regarding the indications, usage and dosage of the TF. Our group demonstrated that the TF increases the expression of IFN-gamma and RANTES, while decreases the expression of osteopontine. Using animal models we have worked with M. tuberculosis, and with a model of glioma with good therapeutic results. In the clinical setting we have worked with herpes zoster, herpes simplex type I, herpetic keratitis, atopic dermatitis, osteosarcoma, tuberculosis, asthma, post-herpetic neuritis, anergic coccidioidomycosis, leishmaniasis, toxoplasmosis, mucocutaneous candidiasis, pediatric infections produced by diverse pathogen germs, sinusitis, pharyngitis, and otits media. All of these diseases were studied through protocols which main goals were to study the therapeutic effects of the TF, and to establish in a systematic way diverse dosage schema and time for treatment to guide the prescription of the TF.
authors.affiliation: Servicio de Inmunología, Instituto Nacional de Pediatría, S.S.
authors.forename: Renato
authors.initials: R
authors.lastname: Berrón-Pérez
authors.forename: Raúl
authors.initials: R
authors.lastname: Chávez-Sánchez
authors.forename: Iris
authors.initials: I
authors.lastname: Estrada-García
authors.forename: Sara
authors.initials: S
authors.lastname: Espinosa-Padilla
authors.forename: Rudyard
authors.initials: R
authors.lastname: Cortez-Gómez
authors.forename: Ernestina
authors.initials: E
authors.lastname: Serrano-Miranda
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Ondarza-Aguilera
authors.forename: Mayra
authors.initials: M
authors.lastname: Pérez-Tapia
authors.forename: Benjamín
authors.initials: B
authors.lastname: Pineda Olvera
authors.forename: María del Carmen
authors.initials: Mdel C
authors.lastname: Jiménez-Martínez
authors.forename: Abraham
authors.initials: A
authors.lastname: Portugués
authors.forename: Azucena
authors.initials: A
authors.lastname: Rodríguez
authors.forename: Laura
authors.initials: L
authors.lastname: Cano
authors.forename: Pedro Urcino
authors.initials: PU
authors.lastname: Pacheco
authors.forename: Javier
authors.initials: J
authors.lastname: Barrientos
authors.forename: Rommel
authors.initials: R
authors.lastname: Chacón
authors.forename: Jeannet
authors.initials: J
authors.lastname: Serafín
authors.forename: Patricia
authors.initials: P
authors.lastname: Mendez
authors.forename: Abelardo
authors.initials: A
authors.lastname: Monges
authors.forename: Edgar
authors.initials: E
authors.lastname: Cervantes
authors.forename: Sergio
authors.initials: S
authors.lastname: Estrada-Parra
mesh_terms: D000818:Animals; D006801:Humans; D007167:Immunotherapy; D014165:Transfer Factor / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014165:Transfer Factor